An Industry In Transition
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
June 19, 2006 Cover
Volume 84, Issue 25
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
Credit:
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
Asymmetric reaction constructs three new C-C bonds and four stereocenters
Fundamental changes erupt across the industry as companies strive to improve drug efficacy and safety and R&D efficiency in the face of negative public opinion
To eliminate R&D bottlenecks, drug companies are evaluating all phases of discovery and development and are using novel approaches to speed them up
Researchers Are Admonished To Stay Focused
FDA Process Guidelines Encourage Efficient Plant Controls
Strong action on drug safety and pricing is more likely to come from states than from Congress or FDA